CANCER RESEARCH-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2147876, encodeId=9bf2214e8765b, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：蛋白质翻译后修饰;肿瘤 经验分享：请问大家proof结束后多久能有排好版的文章上线啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:32:28 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2145679, encodeId=996121456e992, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投过三次，送外审会通知你。 第一次外审1个月，三个审稿人，意见都不乐观，被拒。改投oncogene，中。 第二次外审1个月，三个审稿意见，一个乐观，2个中性，大修后接受，从投稿到接受用了4个月。 第三次，合作文章，并列作者，秒拒。 编辑的态度不错，回复问题很及时。投稿系统bug非常多！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd8b8736567, createdName=ms4000000933785288, createdTime=Fri Jun 30 16:32:39 CST 2023, time=2023-06-30, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2109990, encodeId=f6a9210999082, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：比较难搞，第一稿 Stage Start Date Revision Received 2022-07-15 09:55:14 Waiting for Revision 2022-01-18 09:15:09 Decision Sent to Author 2022-01-18 09:15:09 Decision Pending 2022-01-18 07:43:20 Under Review 2021-12-15 16:40:12 Under Editorial Consideration 2021-12-15 10:25:39 Initial QC 2021-12-13 07:05:17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=482d4748397, createdName=hhhhhccc, createdTime=Thu Jan 12 20:15:37 CST 2023, time=2023-01-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2128280, encodeId=dbfb212828078, content=请问这个杂质接收以后需要提交原始数据吗？提交什么格式的原始数据呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5e1735331, createdName=爱的橙子蓝, createdTime=Tue Apr 25 18:42:56 CST 2023, time=2023-04-25, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=558040, encodeId=d91b55804092, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一稿，小修： Stage Start Date Waiting for Revision 2018-05-01 11:24:14 Decision Sent to Author 2018-05-01 11:24:14 Under Review 2018-04-30 17:54:03 Decision Pending 2018-04-30 17:53:41 Under Review 2018-04-02 16:34:31 Under Editorial Consideration 2018-04-02 15:53:37 Initial QC 2018-04-02 10:23:42 Manuscript Submission 2018-04-02 04:57:41 第二稿，格式修改： 编辑给重新写了摘要，改了标题。 Waiting for Revision 2018-06-08 13:31:15 Decision Sent to Author 2018-06-08 13:31:15 Under Review 2018-06-05 20:21:13 Decision Pending 2018-06-05 20:20:58 Under Review 2018-05-23 10:44:35 Under Editorial Consideration 2018-05-23 04:33:34 Manuscript Submission 2018-05-21 22:28:24 第三稿，接受： Stage Start Date Manuscript Ready for Publication 2018-06-15 11:20:47 Decision Sent to Author 2018-06-15 11:20:47 Under Review 2018-06-15 11:20:22 Decision Pending 2018-06-15 11:20:22 Under Review 2018-06-15 11:20:22 Under Editorial Consideration 2018-06-11 04:36:15 Manuscript Submission 2018-06-10 01:37:25 这个投稿系统附件图片不支持tiff，整到PDF里面分辨率又太低，来来回回跟编辑拉扯了好几次。感觉我们想法不重要，按他们说的来就好了。 希望后面的兄弟姐妹好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=743, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/04/5badf8a0248e81ed1f762a35444fa1de.jpg, createdBy=f1192053852, createdName=小小小蹄子, createdTime=Sat Jun 16 09:18:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803115, encodeId=5cd98031153d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：文章刚刚接收，贴个timeline，供大家参考： 第一稿 Stage Start Date Revision Received 2020-04-09 14:44:05 Waiting for Revision 2020-04-09 14:39:37 Decision Sent to Author 2020-04-09 14:39:37 Decision Pending 2020-04-06 17:45:32 Under Review 2020-03-07 11:36:22 Under Editorial Consideration 2020-03-06 13:06:37 Initial QC 2020-03-05 16:58:41 Manuscript Submission 2020-03-04 16:35:38 第二稿：疫情期间，补了实验 Stage Start Date Revision Received 2020-07-11 06:25:26 Waiting for Revision 2020-07-09 08:38:16 Decision Sent to Author 2020-07-09 08:38:16 Decision Pending 2020-06-29 08:28:42 Under Review 2020-06-25 09:38:03 Under Editorial Consideration 2020-06-23 10:09:56 Manuscript Submission 2020-04-09 14:44:05 第三稿：原则上已经接收，改了一下要求的格式 Stage Start Date Manuscript Ready for Publication 2020-07-16 10:45:24 Decision Sent to Author 2020-07-16 10:45:24 Decision Pending 2020-07-16 10:44:15 Under Review 2020-07-16 10:44:14 Under Editorial Consideration 2020-07-12 05:16:56 Manuscript Submission 2020-07-11 06:25:26 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5e55078563, createdName=Dr. X., createdTime=Fri Jul 17 16:20:42 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114057, encodeId=9208211405e1a, content=好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sat Feb 11 02:03:22 CST 2023, time=2023-02-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=804833, encodeId=4b7080483377, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Stage Start Date Decision Pending 2020-07-27 12:32:30 Under Review 2020-07-27 12:32:23 Under Editorial Consideration 2020-07-27 00:14:55 Initial QC 2020-07-23 09:04:59 Manuscript Submission 2020-07-18 06:59:50 这是我的文章状态，Dr.X你能给分析一下么？谢谢。我的Q是517861267, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:52:18 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108841, encodeId=a66721088411b, content=偏重的研究方向：癌症研究;肿瘤;EMT 经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b5b1736627, createdName=wawljwalj9232, createdTime=Wed Jan 04 22:25:42 CST 2023, time=2023-01-04, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=591364, encodeId=7ca3591364ca, content=二审两个小问题3天修回，pending decision到现在已经9天，CR最近这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2c732016445, createdName=lydia901717, createdTime=Thu May 21 09:18:00 CST 2020, time=2020-05-21, status=1, ipAttribution=)]

2023-07-13 ms9000000602781212 来自北京

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：蛋白质翻译后修饰;肿瘤
经验分享：请问大家proof结束后多久能有排好版的文章上线啊？

61 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2147876, encodeId=9bf2214e8765b, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：蛋白质翻译后修饰;肿瘤 经验分享：请问大家proof结束后多久能有排好版的文章上线啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:32:28 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2145679, encodeId=996121456e992, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投过三次，送外审会通知你。 第一次外审1个月，三个审稿人，意见都不乐观，被拒。改投oncogene，中。 第二次外审1个月，三个审稿意见，一个乐观，2个中性，大修后接受，从投稿到接受用了4个月。 第三次，合作文章，并列作者，秒拒。 编辑的态度不错，回复问题很及时。投稿系统bug非常多！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd8b8736567, createdName=ms4000000933785288, createdTime=Fri Jun 30 16:32:39 CST 2023, time=2023-06-30, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2109990, encodeId=f6a9210999082, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：比较难搞，第一稿 Stage Start Date Revision Received 2022-07-15 09:55:14 Waiting for Revision 2022-01-18 09:15:09 Decision Sent to Author 2022-01-18 09:15:09 Decision Pending 2022-01-18 07:43:20 Under Review 2021-12-15 16:40:12 Under Editorial Consideration 2021-12-15 10:25:39 Initial QC 2021-12-13 07:05:17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=482d4748397, createdName=hhhhhccc, createdTime=Thu Jan 12 20:15:37 CST 2023, time=2023-01-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2128280, encodeId=dbfb212828078, content=请问这个杂质接收以后需要提交原始数据吗？提交什么格式的原始数据呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5e1735331, createdName=爱的橙子蓝, createdTime=Tue Apr 25 18:42:56 CST 2023, time=2023-04-25, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=558040, encodeId=d91b55804092, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一稿，小修： Stage Start Date Waiting for Revision 2018-05-01 11:24:14 Decision Sent to Author 2018-05-01 11:24:14 Under Review 2018-04-30 17:54:03 Decision Pending 2018-04-30 17:53:41 Under Review 2018-04-02 16:34:31 Under Editorial Consideration 2018-04-02 15:53:37 Initial QC 2018-04-02 10:23:42 Manuscript Submission 2018-04-02 04:57:41 第二稿，格式修改： 编辑给重新写了摘要，改了标题。 Waiting for Revision 2018-06-08 13:31:15 Decision Sent to Author 2018-06-08 13:31:15 Under Review 2018-06-05 20:21:13 Decision Pending 2018-06-05 20:20:58 Under Review 2018-05-23 10:44:35 Under Editorial Consideration 2018-05-23 04:33:34 Manuscript Submission 2018-05-21 22:28:24 第三稿，接受： Stage Start Date Manuscript Ready for Publication 2018-06-15 11:20:47 Decision Sent to Author 2018-06-15 11:20:47 Under Review 2018-06-15 11:20:22 Decision Pending 2018-06-15 11:20:22 Under Review 2018-06-15 11:20:22 Under Editorial Consideration 2018-06-11 04:36:15 Manuscript Submission 2018-06-10 01:37:25 这个投稿系统附件图片不支持tiff，整到PDF里面分辨率又太低，来来回回跟编辑拉扯了好几次。感觉我们想法不重要，按他们说的来就好了。 希望后面的兄弟姐妹好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=743, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/04/5badf8a0248e81ed1f762a35444fa1de.jpg, createdBy=f1192053852, createdName=小小小蹄子, createdTime=Sat Jun 16 09:18:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803115, encodeId=5cd98031153d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：文章刚刚接收，贴个timeline，供大家参考： 第一稿 Stage Start Date Revision Received 2020-04-09 14:44:05 Waiting for Revision 2020-04-09 14:39:37 Decision Sent to Author 2020-04-09 14:39:37 Decision Pending 2020-04-06 17:45:32 Under Review 2020-03-07 11:36:22 Under Editorial Consideration 2020-03-06 13:06:37 Initial QC 2020-03-05 16:58:41 Manuscript Submission 2020-03-04 16:35:38 第二稿：疫情期间，补了实验 Stage Start Date Revision Received 2020-07-11 06:25:26 Waiting for Revision 2020-07-09 08:38:16 Decision Sent to Author 2020-07-09 08:38:16 Decision Pending 2020-06-29 08:28:42 Under Review 2020-06-25 09:38:03 Under Editorial Consideration 2020-06-23 10:09:56 Manuscript Submission 2020-04-09 14:44:05 第三稿：原则上已经接收，改了一下要求的格式 Stage Start Date Manuscript Ready for Publication 2020-07-16 10:45:24 Decision Sent to Author 2020-07-16 10:45:24 Decision Pending 2020-07-16 10:44:15 Under Review 2020-07-16 10:44:14 Under Editorial Consideration 2020-07-12 05:16:56 Manuscript Submission 2020-07-11 06:25:26 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5e55078563, createdName=Dr. X., createdTime=Fri Jul 17 16:20:42 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114057, encodeId=9208211405e1a, content=好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sat Feb 11 02:03:22 CST 2023, time=2023-02-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=804833, encodeId=4b7080483377, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Stage Start Date Decision Pending 2020-07-27 12:32:30 Under Review 2020-07-27 12:32:23 Under Editorial Consideration 2020-07-27 00:14:55 Initial QC 2020-07-23 09:04:59 Manuscript Submission 2020-07-18 06:59:50 这是我的文章状态，Dr.X你能给分析一下么？谢谢。我的Q是517861267, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:52:18 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108841, encodeId=a66721088411b, content=偏重的研究方向：癌症研究;肿瘤;EMT 经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b5b1736627, createdName=wawljwalj9232, createdTime=Wed Jan 04 22:25:42 CST 2023, time=2023-01-04, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=591364, encodeId=7ca3591364ca, content=二审两个小问题3天修回，pending decision到现在已经9天，CR最近这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2c732016445, createdName=lydia901717, createdTime=Thu May 21 09:18:00 CST 2020, time=2020-05-21, status=1, ipAttribution=)]

2023-06-30 ms4000000933785288 来自香港

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤
经验分享：投过三次，送外审会通知你。
第一次外审1个月，三个审稿人，意见都不乐观，被拒。改投oncogene，中。
第二次外审1个月，三个审稿意见，一个乐观，2个中性，大修后接受，从投稿到接受用了4个月。
第三次，合作文章，并列作者，秒拒。
编辑的态度不错，回复问题很及时。投稿系统bug非常多！

90 0

[GetPortalCommentsPageByObjectIdResponse(id=2147876, encodeId=9bf2214e8765b, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：蛋白质翻译后修饰;肿瘤 经验分享：请问大家proof结束后多久能有排好版的文章上线啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:32:28 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2145679, encodeId=996121456e992, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投过三次，送外审会通知你。 第一次外审1个月，三个审稿人，意见都不乐观，被拒。改投oncogene，中。 第二次外审1个月，三个审稿意见，一个乐观，2个中性，大修后接受，从投稿到接受用了4个月。 第三次，合作文章，并列作者，秒拒。 编辑的态度不错，回复问题很及时。投稿系统bug非常多！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd8b8736567, createdName=ms4000000933785288, createdTime=Fri Jun 30 16:32:39 CST 2023, time=2023-06-30, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2109990, encodeId=f6a9210999082, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：比较难搞，第一稿 Stage Start Date Revision Received 2022-07-15 09:55:14 Waiting for Revision 2022-01-18 09:15:09 Decision Sent to Author 2022-01-18 09:15:09 Decision Pending 2022-01-18 07:43:20 Under Review 2021-12-15 16:40:12 Under Editorial Consideration 2021-12-15 10:25:39 Initial QC 2021-12-13 07:05:17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=482d4748397, createdName=hhhhhccc, createdTime=Thu Jan 12 20:15:37 CST 2023, time=2023-01-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2128280, encodeId=dbfb212828078, content=请问这个杂质接收以后需要提交原始数据吗？提交什么格式的原始数据呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5e1735331, createdName=爱的橙子蓝, createdTime=Tue Apr 25 18:42:56 CST 2023, time=2023-04-25, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=558040, encodeId=d91b55804092, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一稿，小修： Stage Start Date Waiting for Revision 2018-05-01 11:24:14 Decision Sent to Author 2018-05-01 11:24:14 Under Review 2018-04-30 17:54:03 Decision Pending 2018-04-30 17:53:41 Under Review 2018-04-02 16:34:31 Under Editorial Consideration 2018-04-02 15:53:37 Initial QC 2018-04-02 10:23:42 Manuscript Submission 2018-04-02 04:57:41 第二稿，格式修改： 编辑给重新写了摘要，改了标题。 Waiting for Revision 2018-06-08 13:31:15 Decision Sent to Author 2018-06-08 13:31:15 Under Review 2018-06-05 20:21:13 Decision Pending 2018-06-05 20:20:58 Under Review 2018-05-23 10:44:35 Under Editorial Consideration 2018-05-23 04:33:34 Manuscript Submission 2018-05-21 22:28:24 第三稿，接受： Stage Start Date Manuscript Ready for Publication 2018-06-15 11:20:47 Decision Sent to Author 2018-06-15 11:20:47 Under Review 2018-06-15 11:20:22 Decision Pending 2018-06-15 11:20:22 Under Review 2018-06-15 11:20:22 Under Editorial Consideration 2018-06-11 04:36:15 Manuscript Submission 2018-06-10 01:37:25 这个投稿系统附件图片不支持tiff，整到PDF里面分辨率又太低，来来回回跟编辑拉扯了好几次。感觉我们想法不重要，按他们说的来就好了。 希望后面的兄弟姐妹好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=743, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/04/5badf8a0248e81ed1f762a35444fa1de.jpg, createdBy=f1192053852, createdName=小小小蹄子, createdTime=Sat Jun 16 09:18:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803115, encodeId=5cd98031153d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：文章刚刚接收，贴个timeline，供大家参考： 第一稿 Stage Start Date Revision Received 2020-04-09 14:44:05 Waiting for Revision 2020-04-09 14:39:37 Decision Sent to Author 2020-04-09 14:39:37 Decision Pending 2020-04-06 17:45:32 Under Review 2020-03-07 11:36:22 Under Editorial Consideration 2020-03-06 13:06:37 Initial QC 2020-03-05 16:58:41 Manuscript Submission 2020-03-04 16:35:38 第二稿：疫情期间，补了实验 Stage Start Date Revision Received 2020-07-11 06:25:26 Waiting for Revision 2020-07-09 08:38:16 Decision Sent to Author 2020-07-09 08:38:16 Decision Pending 2020-06-29 08:28:42 Under Review 2020-06-25 09:38:03 Under Editorial Consideration 2020-06-23 10:09:56 Manuscript Submission 2020-04-09 14:44:05 第三稿：原则上已经接收，改了一下要求的格式 Stage Start Date Manuscript Ready for Publication 2020-07-16 10:45:24 Decision Sent to Author 2020-07-16 10:45:24 Decision Pending 2020-07-16 10:44:15 Under Review 2020-07-16 10:44:14 Under Editorial Consideration 2020-07-12 05:16:56 Manuscript Submission 2020-07-11 06:25:26 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5e55078563, createdName=Dr. X., createdTime=Fri Jul 17 16:20:42 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114057, encodeId=9208211405e1a, content=好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sat Feb 11 02:03:22 CST 2023, time=2023-02-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=804833, encodeId=4b7080483377, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Stage Start Date Decision Pending 2020-07-27 12:32:30 Under Review 2020-07-27 12:32:23 Under Editorial Consideration 2020-07-27 00:14:55 Initial QC 2020-07-23 09:04:59 Manuscript Submission 2020-07-18 06:59:50 这是我的文章状态，Dr.X你能给分析一下么？谢谢。我的Q是517861267, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:52:18 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108841, encodeId=a66721088411b, content=偏重的研究方向：癌症研究;肿瘤;EMT 经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b5b1736627, createdName=wawljwalj9232, createdTime=Wed Jan 04 22:25:42 CST 2023, time=2023-01-04, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=591364, encodeId=7ca3591364ca, content=二审两个小问题3天修回，pending decision到现在已经9天，CR最近这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2c732016445, createdName=lydia901717, createdTime=Thu May 21 09:18:00 CST 2020, time=2020-05-21, status=1, ipAttribution=)]

2023-01-12 hhhhhccc 来自广东省

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤研究
经验分享：比较难搞，第一稿
Stage Start Date
Revision Received 2022-07-15 09:55:14
Waiting for Revision 2022-01-18 09:15:09
Decision Sent to Author 2022-01-18 09:15:09
Decision Pending 2022-01-18 07:43:20
Under Review 2021-12-15 16:40:12
Under Editorial Consideration 2021-12-15 10:25:39
Initial QC 2021-12-13 07:05:17

123 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2147876, encodeId=9bf2214e8765b, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：蛋白质翻译后修饰;肿瘤 经验分享：请问大家proof结束后多久能有排好版的文章上线啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:32:28 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2145679, encodeId=996121456e992, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投过三次，送外审会通知你。 第一次外审1个月，三个审稿人，意见都不乐观，被拒。改投oncogene，中。 第二次外审1个月，三个审稿意见，一个乐观，2个中性，大修后接受，从投稿到接受用了4个月。 第三次，合作文章，并列作者，秒拒。 编辑的态度不错，回复问题很及时。投稿系统bug非常多！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd8b8736567, createdName=ms4000000933785288, createdTime=Fri Jun 30 16:32:39 CST 2023, time=2023-06-30, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2109990, encodeId=f6a9210999082, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：比较难搞，第一稿 Stage Start Date Revision Received 2022-07-15 09:55:14 Waiting for Revision 2022-01-18 09:15:09 Decision Sent to Author 2022-01-18 09:15:09 Decision Pending 2022-01-18 07:43:20 Under Review 2021-12-15 16:40:12 Under Editorial Consideration 2021-12-15 10:25:39 Initial QC 2021-12-13 07:05:17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=482d4748397, createdName=hhhhhccc, createdTime=Thu Jan 12 20:15:37 CST 2023, time=2023-01-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2128280, encodeId=dbfb212828078, content=请问这个杂质接收以后需要提交原始数据吗？提交什么格式的原始数据呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5e1735331, createdName=爱的橙子蓝, createdTime=Tue Apr 25 18:42:56 CST 2023, time=2023-04-25, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=558040, encodeId=d91b55804092, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一稿，小修： Stage Start Date Waiting for Revision 2018-05-01 11:24:14 Decision Sent to Author 2018-05-01 11:24:14 Under Review 2018-04-30 17:54:03 Decision Pending 2018-04-30 17:53:41 Under Review 2018-04-02 16:34:31 Under Editorial Consideration 2018-04-02 15:53:37 Initial QC 2018-04-02 10:23:42 Manuscript Submission 2018-04-02 04:57:41 第二稿，格式修改： 编辑给重新写了摘要，改了标题。 Waiting for Revision 2018-06-08 13:31:15 Decision Sent to Author 2018-06-08 13:31:15 Under Review 2018-06-05 20:21:13 Decision Pending 2018-06-05 20:20:58 Under Review 2018-05-23 10:44:35 Under Editorial Consideration 2018-05-23 04:33:34 Manuscript Submission 2018-05-21 22:28:24 第三稿，接受： Stage Start Date Manuscript Ready for Publication 2018-06-15 11:20:47 Decision Sent to Author 2018-06-15 11:20:47 Under Review 2018-06-15 11:20:22 Decision Pending 2018-06-15 11:20:22 Under Review 2018-06-15 11:20:22 Under Editorial Consideration 2018-06-11 04:36:15 Manuscript Submission 2018-06-10 01:37:25 这个投稿系统附件图片不支持tiff，整到PDF里面分辨率又太低，来来回回跟编辑拉扯了好几次。感觉我们想法不重要，按他们说的来就好了。 希望后面的兄弟姐妹好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=743, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/04/5badf8a0248e81ed1f762a35444fa1de.jpg, createdBy=f1192053852, createdName=小小小蹄子, createdTime=Sat Jun 16 09:18:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803115, encodeId=5cd98031153d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：文章刚刚接收，贴个timeline，供大家参考： 第一稿 Stage Start Date Revision Received 2020-04-09 14:44:05 Waiting for Revision 2020-04-09 14:39:37 Decision Sent to Author 2020-04-09 14:39:37 Decision Pending 2020-04-06 17:45:32 Under Review 2020-03-07 11:36:22 Under Editorial Consideration 2020-03-06 13:06:37 Initial QC 2020-03-05 16:58:41 Manuscript Submission 2020-03-04 16:35:38 第二稿：疫情期间，补了实验 Stage Start Date Revision Received 2020-07-11 06:25:26 Waiting for Revision 2020-07-09 08:38:16 Decision Sent to Author 2020-07-09 08:38:16 Decision Pending 2020-06-29 08:28:42 Under Review 2020-06-25 09:38:03 Under Editorial Consideration 2020-06-23 10:09:56 Manuscript Submission 2020-04-09 14:44:05 第三稿：原则上已经接收，改了一下要求的格式 Stage Start Date Manuscript Ready for Publication 2020-07-16 10:45:24 Decision Sent to Author 2020-07-16 10:45:24 Decision Pending 2020-07-16 10:44:15 Under Review 2020-07-16 10:44:14 Under Editorial Consideration 2020-07-12 05:16:56 Manuscript Submission 2020-07-11 06:25:26 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5e55078563, createdName=Dr. X., createdTime=Fri Jul 17 16:20:42 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114057, encodeId=9208211405e1a, content=好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sat Feb 11 02:03:22 CST 2023, time=2023-02-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=804833, encodeId=4b7080483377, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Stage Start Date Decision Pending 2020-07-27 12:32:30 Under Review 2020-07-27 12:32:23 Under Editorial Consideration 2020-07-27 00:14:55 Initial QC 2020-07-23 09:04:59 Manuscript Submission 2020-07-18 06:59:50 这是我的文章状态，Dr.X你能给分析一下么？谢谢。我的Q是517861267, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:52:18 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108841, encodeId=a66721088411b, content=偏重的研究方向：癌症研究;肿瘤;EMT 经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b5b1736627, createdName=wawljwalj9232, createdTime=Wed Jan 04 22:25:42 CST 2023, time=2023-01-04, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=591364, encodeId=7ca3591364ca, content=二审两个小问题3天修回，pending decision到现在已经9天，CR最近这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2c732016445, createdName=lydia901717, createdTime=Thu May 21 09:18:00 CST 2020, time=2020-05-21, status=1, ipAttribution=)]

2023-04-25 爱的橙子蓝来自天津

请问这个杂质接收以后需要提交原始数据吗？提交什么格式的原始数据呀

78 0

[GetPortalCommentsPageByObjectIdResponse(id=2147876, encodeId=9bf2214e8765b, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：蛋白质翻译后修饰;肿瘤 经验分享：请问大家proof结束后多久能有排好版的文章上线啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:32:28 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2145679, encodeId=996121456e992, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投过三次，送外审会通知你。 第一次外审1个月，三个审稿人，意见都不乐观，被拒。改投oncogene，中。 第二次外审1个月，三个审稿意见，一个乐观，2个中性，大修后接受，从投稿到接受用了4个月。 第三次，合作文章，并列作者，秒拒。 编辑的态度不错，回复问题很及时。投稿系统bug非常多！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd8b8736567, createdName=ms4000000933785288, createdTime=Fri Jun 30 16:32:39 CST 2023, time=2023-06-30, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2109990, encodeId=f6a9210999082, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：比较难搞，第一稿 Stage Start Date Revision Received 2022-07-15 09:55:14 Waiting for Revision 2022-01-18 09:15:09 Decision Sent to Author 2022-01-18 09:15:09 Decision Pending 2022-01-18 07:43:20 Under Review 2021-12-15 16:40:12 Under Editorial Consideration 2021-12-15 10:25:39 Initial QC 2021-12-13 07:05:17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=482d4748397, createdName=hhhhhccc, createdTime=Thu Jan 12 20:15:37 CST 2023, time=2023-01-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2128280, encodeId=dbfb212828078, content=请问这个杂质接收以后需要提交原始数据吗？提交什么格式的原始数据呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5e1735331, createdName=爱的橙子蓝, createdTime=Tue Apr 25 18:42:56 CST 2023, time=2023-04-25, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=558040, encodeId=d91b55804092, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一稿，小修： Stage Start Date Waiting for Revision 2018-05-01 11:24:14 Decision Sent to Author 2018-05-01 11:24:14 Under Review 2018-04-30 17:54:03 Decision Pending 2018-04-30 17:53:41 Under Review 2018-04-02 16:34:31 Under Editorial Consideration 2018-04-02 15:53:37 Initial QC 2018-04-02 10:23:42 Manuscript Submission 2018-04-02 04:57:41 第二稿，格式修改： 编辑给重新写了摘要，改了标题。 Waiting for Revision 2018-06-08 13:31:15 Decision Sent to Author 2018-06-08 13:31:15 Under Review 2018-06-05 20:21:13 Decision Pending 2018-06-05 20:20:58 Under Review 2018-05-23 10:44:35 Under Editorial Consideration 2018-05-23 04:33:34 Manuscript Submission 2018-05-21 22:28:24 第三稿，接受： Stage Start Date Manuscript Ready for Publication 2018-06-15 11:20:47 Decision Sent to Author 2018-06-15 11:20:47 Under Review 2018-06-15 11:20:22 Decision Pending 2018-06-15 11:20:22 Under Review 2018-06-15 11:20:22 Under Editorial Consideration 2018-06-11 04:36:15 Manuscript Submission 2018-06-10 01:37:25 这个投稿系统附件图片不支持tiff，整到PDF里面分辨率又太低，来来回回跟编辑拉扯了好几次。感觉我们想法不重要，按他们说的来就好了。 希望后面的兄弟姐妹好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=743, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/04/5badf8a0248e81ed1f762a35444fa1de.jpg, createdBy=f1192053852, createdName=小小小蹄子, createdTime=Sat Jun 16 09:18:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803115, encodeId=5cd98031153d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：文章刚刚接收，贴个timeline，供大家参考： 第一稿 Stage Start Date Revision Received 2020-04-09 14:44:05 Waiting for Revision 2020-04-09 14:39:37 Decision Sent to Author 2020-04-09 14:39:37 Decision Pending 2020-04-06 17:45:32 Under Review 2020-03-07 11:36:22 Under Editorial Consideration 2020-03-06 13:06:37 Initial QC 2020-03-05 16:58:41 Manuscript Submission 2020-03-04 16:35:38 第二稿：疫情期间，补了实验 Stage Start Date Revision Received 2020-07-11 06:25:26 Waiting for Revision 2020-07-09 08:38:16 Decision Sent to Author 2020-07-09 08:38:16 Decision Pending 2020-06-29 08:28:42 Under Review 2020-06-25 09:38:03 Under Editorial Consideration 2020-06-23 10:09:56 Manuscript Submission 2020-04-09 14:44:05 第三稿：原则上已经接收，改了一下要求的格式 Stage Start Date Manuscript Ready for Publication 2020-07-16 10:45:24 Decision Sent to Author 2020-07-16 10:45:24 Decision Pending 2020-07-16 10:44:15 Under Review 2020-07-16 10:44:14 Under Editorial Consideration 2020-07-12 05:16:56 Manuscript Submission 2020-07-11 06:25:26 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5e55078563, createdName=Dr. X., createdTime=Fri Jul 17 16:20:42 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114057, encodeId=9208211405e1a, content=好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sat Feb 11 02:03:22 CST 2023, time=2023-02-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=804833, encodeId=4b7080483377, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Stage Start Date Decision Pending 2020-07-27 12:32:30 Under Review 2020-07-27 12:32:23 Under Editorial Consideration 2020-07-27 00:14:55 Initial QC 2020-07-23 09:04:59 Manuscript Submission 2020-07-18 06:59:50 这是我的文章状态，Dr.X你能给分析一下么？谢谢。我的Q是517861267, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:52:18 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108841, encodeId=a66721088411b, content=偏重的研究方向：癌症研究;肿瘤;EMT 经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b5b1736627, createdName=wawljwalj9232, createdTime=Wed Jan 04 22:25:42 CST 2023, time=2023-01-04, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=591364, encodeId=7ca3591364ca, content=二审两个小问题3天修回，pending decision到现在已经9天，CR最近这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2c732016445, createdName=lydia901717, createdTime=Thu May 21 09:18:00 CST 2020, time=2020-05-21, status=1, ipAttribution=)]

2018-06-16 小小小蹄子

审稿速度:2.0 | 投稿命中率:25.0
经验分享：第一稿，小修：
Stage Start Date
Waiting for Revision 2018-05-01 11:24:14
Decision Sent to Author 2018-05-01 11:24:14
Under Review 2018-04-30 17:54:03
Decision Pending 2018-04-30 17:53:41
Under Review 2018-04-02 16:34:31
Under Editorial Consideration 2018-04-02 15:53:37
Initial QC 2018-04-02 10:23:42
Manuscript Submission 2018-04-02 04:57:41
第二稿，格式修改：
编辑给重新写了摘要，改了标题。
Waiting for Revision 2018-06-08 13:31:15
Decision Sent to Author 2018-06-08 13:31:15
Under Review 2018-06-05 20:21:13
Decision Pending 2018-06-05 20:20:58
Under Review 2018-05-23 10:44:35
Under Editorial Consideration 2018-05-23 04:33:34
Manuscript Submission 2018-05-21 22:28:24
第三稿，接受：
Stage Start Date
Manuscript Ready for Publication 2018-06-15 11:20:47
Decision Sent to Author 2018-06-15 11:20:47
Under Review 2018-06-15 11:20:22
Decision Pending 2018-06-15 11:20:22
Under Review 2018-06-15 11:20:22
Under Editorial Consideration 2018-06-11 04:36:15
Manuscript Submission 2018-06-10 01:37:25
这个投稿系统附件图片不支持tiff，整到PDF里面分辨率又太低，来来回回跟编辑拉扯了好几次。感觉我们想法不重要，按他们说的来就好了。
希望后面的兄弟姐妹好运。

743 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2147876, encodeId=9bf2214e8765b, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：蛋白质翻译后修饰;肿瘤 经验分享：请问大家proof结束后多久能有排好版的文章上线啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:32:28 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2145679, encodeId=996121456e992, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投过三次，送外审会通知你。 第一次外审1个月，三个审稿人，意见都不乐观，被拒。改投oncogene，中。 第二次外审1个月，三个审稿意见，一个乐观，2个中性，大修后接受，从投稿到接受用了4个月。 第三次，合作文章，并列作者，秒拒。 编辑的态度不错，回复问题很及时。投稿系统bug非常多！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd8b8736567, createdName=ms4000000933785288, createdTime=Fri Jun 30 16:32:39 CST 2023, time=2023-06-30, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2109990, encodeId=f6a9210999082, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：比较难搞，第一稿 Stage Start Date Revision Received 2022-07-15 09:55:14 Waiting for Revision 2022-01-18 09:15:09 Decision Sent to Author 2022-01-18 09:15:09 Decision Pending 2022-01-18 07:43:20 Under Review 2021-12-15 16:40:12 Under Editorial Consideration 2021-12-15 10:25:39 Initial QC 2021-12-13 07:05:17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=482d4748397, createdName=hhhhhccc, createdTime=Thu Jan 12 20:15:37 CST 2023, time=2023-01-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2128280, encodeId=dbfb212828078, content=请问这个杂质接收以后需要提交原始数据吗？提交什么格式的原始数据呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5e1735331, createdName=爱的橙子蓝, createdTime=Tue Apr 25 18:42:56 CST 2023, time=2023-04-25, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=558040, encodeId=d91b55804092, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一稿，小修： Stage Start Date Waiting for Revision 2018-05-01 11:24:14 Decision Sent to Author 2018-05-01 11:24:14 Under Review 2018-04-30 17:54:03 Decision Pending 2018-04-30 17:53:41 Under Review 2018-04-02 16:34:31 Under Editorial Consideration 2018-04-02 15:53:37 Initial QC 2018-04-02 10:23:42 Manuscript Submission 2018-04-02 04:57:41 第二稿，格式修改： 编辑给重新写了摘要，改了标题。 Waiting for Revision 2018-06-08 13:31:15 Decision Sent to Author 2018-06-08 13:31:15 Under Review 2018-06-05 20:21:13 Decision Pending 2018-06-05 20:20:58 Under Review 2018-05-23 10:44:35 Under Editorial Consideration 2018-05-23 04:33:34 Manuscript Submission 2018-05-21 22:28:24 第三稿，接受： Stage Start Date Manuscript Ready for Publication 2018-06-15 11:20:47 Decision Sent to Author 2018-06-15 11:20:47 Under Review 2018-06-15 11:20:22 Decision Pending 2018-06-15 11:20:22 Under Review 2018-06-15 11:20:22 Under Editorial Consideration 2018-06-11 04:36:15 Manuscript Submission 2018-06-10 01:37:25 这个投稿系统附件图片不支持tiff，整到PDF里面分辨率又太低，来来回回跟编辑拉扯了好几次。感觉我们想法不重要，按他们说的来就好了。 希望后面的兄弟姐妹好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=743, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/04/5badf8a0248e81ed1f762a35444fa1de.jpg, createdBy=f1192053852, createdName=小小小蹄子, createdTime=Sat Jun 16 09:18:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803115, encodeId=5cd98031153d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：文章刚刚接收，贴个timeline，供大家参考： 第一稿 Stage Start Date Revision Received 2020-04-09 14:44:05 Waiting for Revision 2020-04-09 14:39:37 Decision Sent to Author 2020-04-09 14:39:37 Decision Pending 2020-04-06 17:45:32 Under Review 2020-03-07 11:36:22 Under Editorial Consideration 2020-03-06 13:06:37 Initial QC 2020-03-05 16:58:41 Manuscript Submission 2020-03-04 16:35:38 第二稿：疫情期间，补了实验 Stage Start Date Revision Received 2020-07-11 06:25:26 Waiting for Revision 2020-07-09 08:38:16 Decision Sent to Author 2020-07-09 08:38:16 Decision Pending 2020-06-29 08:28:42 Under Review 2020-06-25 09:38:03 Under Editorial Consideration 2020-06-23 10:09:56 Manuscript Submission 2020-04-09 14:44:05 第三稿：原则上已经接收，改了一下要求的格式 Stage Start Date Manuscript Ready for Publication 2020-07-16 10:45:24 Decision Sent to Author 2020-07-16 10:45:24 Decision Pending 2020-07-16 10:44:15 Under Review 2020-07-16 10:44:14 Under Editorial Consideration 2020-07-12 05:16:56 Manuscript Submission 2020-07-11 06:25:26 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5e55078563, createdName=Dr. X., createdTime=Fri Jul 17 16:20:42 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114057, encodeId=9208211405e1a, content=好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sat Feb 11 02:03:22 CST 2023, time=2023-02-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=804833, encodeId=4b7080483377, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Stage Start Date Decision Pending 2020-07-27 12:32:30 Under Review 2020-07-27 12:32:23 Under Editorial Consideration 2020-07-27 00:14:55 Initial QC 2020-07-23 09:04:59 Manuscript Submission 2020-07-18 06:59:50 这是我的文章状态，Dr.X你能给分析一下么？谢谢。我的Q是517861267, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:52:18 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108841, encodeId=a66721088411b, content=偏重的研究方向：癌症研究;肿瘤;EMT 经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b5b1736627, createdName=wawljwalj9232, createdTime=Wed Jan 04 22:25:42 CST 2023, time=2023-01-04, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=591364, encodeId=7ca3591364ca, content=二审两个小问题3天修回，pending decision到现在已经9天，CR最近这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2c732016445, createdName=lydia901717, createdTime=Thu May 21 09:18:00 CST 2020, time=2020-05-21, status=1, ipAttribution=)]

2020-07-17 Dr. X.

审稿速度:1.0 | 投稿命中率:50.0
经验分享：文章刚刚接收，贴个timeline，供大家参考：
第一稿
Stage Start Date
Revision Received 2020-04-09 14:44:05
Waiting for Revision 2020-04-09 14:39:37
Decision Sent to Author 2020-04-09 14:39:37
Decision Pending 2020-04-06 17:45:32
Under Review 2020-03-07 11:36:22
Under Editorial Consideration 2020-03-06 13:06:37
Initial QC 2020-03-05 16:58:41
Manuscript Submission 2020-03-04 16:35:38
第二稿：疫情期间，补了实验
Stage Start Date
Revision Received 2020-07-11 06:25:26
Waiting for Revision 2020-07-09 08:38:16
Decision Sent to Author 2020-07-09 08:38:16
Decision Pending 2020-06-29 08:28:42
Under Review 2020-06-25 09:38:03
Under Editorial Consideration 2020-06-23 10:09:56
Manuscript Submission 2020-04-09 14:44:05
第三稿：原则上已经接收，改了一下要求的格式
Stage Start Date
Manuscript Ready for Publication 2020-07-16 10:45:24
Decision Sent to Author 2020-07-16 10:45:24
Decision Pending 2020-07-16 10:44:15
Under Review 2020-07-16 10:44:14
Under Editorial Consideration 2020-07-12 05:16:56
Manuscript Submission 2020-07-11 06:25:26

266 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2147876, encodeId=9bf2214e8765b, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：蛋白质翻译后修饰;肿瘤 经验分享：请问大家proof结束后多久能有排好版的文章上线啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:32:28 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2145679, encodeId=996121456e992, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投过三次，送外审会通知你。 第一次外审1个月，三个审稿人，意见都不乐观，被拒。改投oncogene，中。 第二次外审1个月，三个审稿意见，一个乐观，2个中性，大修后接受，从投稿到接受用了4个月。 第三次，合作文章，并列作者，秒拒。 编辑的态度不错，回复问题很及时。投稿系统bug非常多！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd8b8736567, createdName=ms4000000933785288, createdTime=Fri Jun 30 16:32:39 CST 2023, time=2023-06-30, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2109990, encodeId=f6a9210999082, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：比较难搞，第一稿 Stage Start Date Revision Received 2022-07-15 09:55:14 Waiting for Revision 2022-01-18 09:15:09 Decision Sent to Author 2022-01-18 09:15:09 Decision Pending 2022-01-18 07:43:20 Under Review 2021-12-15 16:40:12 Under Editorial Consideration 2021-12-15 10:25:39 Initial QC 2021-12-13 07:05:17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=482d4748397, createdName=hhhhhccc, createdTime=Thu Jan 12 20:15:37 CST 2023, time=2023-01-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2128280, encodeId=dbfb212828078, content=请问这个杂质接收以后需要提交原始数据吗？提交什么格式的原始数据呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5e1735331, createdName=爱的橙子蓝, createdTime=Tue Apr 25 18:42:56 CST 2023, time=2023-04-25, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=558040, encodeId=d91b55804092, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一稿，小修： Stage Start Date Waiting for Revision 2018-05-01 11:24:14 Decision Sent to Author 2018-05-01 11:24:14 Under Review 2018-04-30 17:54:03 Decision Pending 2018-04-30 17:53:41 Under Review 2018-04-02 16:34:31 Under Editorial Consideration 2018-04-02 15:53:37 Initial QC 2018-04-02 10:23:42 Manuscript Submission 2018-04-02 04:57:41 第二稿，格式修改： 编辑给重新写了摘要，改了标题。 Waiting for Revision 2018-06-08 13:31:15 Decision Sent to Author 2018-06-08 13:31:15 Under Review 2018-06-05 20:21:13 Decision Pending 2018-06-05 20:20:58 Under Review 2018-05-23 10:44:35 Under Editorial Consideration 2018-05-23 04:33:34 Manuscript Submission 2018-05-21 22:28:24 第三稿，接受： Stage Start Date Manuscript Ready for Publication 2018-06-15 11:20:47 Decision Sent to Author 2018-06-15 11:20:47 Under Review 2018-06-15 11:20:22 Decision Pending 2018-06-15 11:20:22 Under Review 2018-06-15 11:20:22 Under Editorial Consideration 2018-06-11 04:36:15 Manuscript Submission 2018-06-10 01:37:25 这个投稿系统附件图片不支持tiff，整到PDF里面分辨率又太低，来来回回跟编辑拉扯了好几次。感觉我们想法不重要，按他们说的来就好了。 希望后面的兄弟姐妹好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=743, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/04/5badf8a0248e81ed1f762a35444fa1de.jpg, createdBy=f1192053852, createdName=小小小蹄子, createdTime=Sat Jun 16 09:18:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803115, encodeId=5cd98031153d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：文章刚刚接收，贴个timeline，供大家参考： 第一稿 Stage Start Date Revision Received 2020-04-09 14:44:05 Waiting for Revision 2020-04-09 14:39:37 Decision Sent to Author 2020-04-09 14:39:37 Decision Pending 2020-04-06 17:45:32 Under Review 2020-03-07 11:36:22 Under Editorial Consideration 2020-03-06 13:06:37 Initial QC 2020-03-05 16:58:41 Manuscript Submission 2020-03-04 16:35:38 第二稿：疫情期间，补了实验 Stage Start Date Revision Received 2020-07-11 06:25:26 Waiting for Revision 2020-07-09 08:38:16 Decision Sent to Author 2020-07-09 08:38:16 Decision Pending 2020-06-29 08:28:42 Under Review 2020-06-25 09:38:03 Under Editorial Consideration 2020-06-23 10:09:56 Manuscript Submission 2020-04-09 14:44:05 第三稿：原则上已经接收，改了一下要求的格式 Stage Start Date Manuscript Ready for Publication 2020-07-16 10:45:24 Decision Sent to Author 2020-07-16 10:45:24 Decision Pending 2020-07-16 10:44:15 Under Review 2020-07-16 10:44:14 Under Editorial Consideration 2020-07-12 05:16:56 Manuscript Submission 2020-07-11 06:25:26 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5e55078563, createdName=Dr. X., createdTime=Fri Jul 17 16:20:42 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114057, encodeId=9208211405e1a, content=好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sat Feb 11 02:03:22 CST 2023, time=2023-02-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=804833, encodeId=4b7080483377, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Stage Start Date Decision Pending 2020-07-27 12:32:30 Under Review 2020-07-27 12:32:23 Under Editorial Consideration 2020-07-27 00:14:55 Initial QC 2020-07-23 09:04:59 Manuscript Submission 2020-07-18 06:59:50 这是我的文章状态，Dr.X你能给分析一下么？谢谢。我的Q是517861267, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:52:18 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108841, encodeId=a66721088411b, content=偏重的研究方向：癌症研究;肿瘤;EMT 经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b5b1736627, createdName=wawljwalj9232, createdTime=Wed Jan 04 22:25:42 CST 2023, time=2023-01-04, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=591364, encodeId=7ca3591364ca, content=二审两个小问题3天修回，pending decision到现在已经9天，CR最近这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2c732016445, createdName=lydia901717, createdTime=Thu May 21 09:18:00 CST 2020, time=2020-05-21, status=1, ipAttribution=)]

2023-02-11 osmataku 来自北京

好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段

97 0

[GetPortalCommentsPageByObjectIdResponse(id=2147876, encodeId=9bf2214e8765b, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：蛋白质翻译后修饰;肿瘤 经验分享：请问大家proof结束后多久能有排好版的文章上线啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:32:28 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2145679, encodeId=996121456e992, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投过三次，送外审会通知你。 第一次外审1个月，三个审稿人，意见都不乐观，被拒。改投oncogene，中。 第二次外审1个月，三个审稿意见，一个乐观，2个中性，大修后接受，从投稿到接受用了4个月。 第三次，合作文章，并列作者，秒拒。 编辑的态度不错，回复问题很及时。投稿系统bug非常多！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd8b8736567, createdName=ms4000000933785288, createdTime=Fri Jun 30 16:32:39 CST 2023, time=2023-06-30, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2109990, encodeId=f6a9210999082, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：比较难搞，第一稿 Stage Start Date Revision Received 2022-07-15 09:55:14 Waiting for Revision 2022-01-18 09:15:09 Decision Sent to Author 2022-01-18 09:15:09 Decision Pending 2022-01-18 07:43:20 Under Review 2021-12-15 16:40:12 Under Editorial Consideration 2021-12-15 10:25:39 Initial QC 2021-12-13 07:05:17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=482d4748397, createdName=hhhhhccc, createdTime=Thu Jan 12 20:15:37 CST 2023, time=2023-01-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2128280, encodeId=dbfb212828078, content=请问这个杂质接收以后需要提交原始数据吗？提交什么格式的原始数据呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5e1735331, createdName=爱的橙子蓝, createdTime=Tue Apr 25 18:42:56 CST 2023, time=2023-04-25, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=558040, encodeId=d91b55804092, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一稿，小修： Stage Start Date Waiting for Revision 2018-05-01 11:24:14 Decision Sent to Author 2018-05-01 11:24:14 Under Review 2018-04-30 17:54:03 Decision Pending 2018-04-30 17:53:41 Under Review 2018-04-02 16:34:31 Under Editorial Consideration 2018-04-02 15:53:37 Initial QC 2018-04-02 10:23:42 Manuscript Submission 2018-04-02 04:57:41 第二稿，格式修改： 编辑给重新写了摘要，改了标题。 Waiting for Revision 2018-06-08 13:31:15 Decision Sent to Author 2018-06-08 13:31:15 Under Review 2018-06-05 20:21:13 Decision Pending 2018-06-05 20:20:58 Under Review 2018-05-23 10:44:35 Under Editorial Consideration 2018-05-23 04:33:34 Manuscript Submission 2018-05-21 22:28:24 第三稿，接受： Stage Start Date Manuscript Ready for Publication 2018-06-15 11:20:47 Decision Sent to Author 2018-06-15 11:20:47 Under Review 2018-06-15 11:20:22 Decision Pending 2018-06-15 11:20:22 Under Review 2018-06-15 11:20:22 Under Editorial Consideration 2018-06-11 04:36:15 Manuscript Submission 2018-06-10 01:37:25 这个投稿系统附件图片不支持tiff，整到PDF里面分辨率又太低，来来回回跟编辑拉扯了好几次。感觉我们想法不重要，按他们说的来就好了。 希望后面的兄弟姐妹好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=743, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/04/5badf8a0248e81ed1f762a35444fa1de.jpg, createdBy=f1192053852, createdName=小小小蹄子, createdTime=Sat Jun 16 09:18:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803115, encodeId=5cd98031153d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：文章刚刚接收，贴个timeline，供大家参考： 第一稿 Stage Start Date Revision Received 2020-04-09 14:44:05 Waiting for Revision 2020-04-09 14:39:37 Decision Sent to Author 2020-04-09 14:39:37 Decision Pending 2020-04-06 17:45:32 Under Review 2020-03-07 11:36:22 Under Editorial Consideration 2020-03-06 13:06:37 Initial QC 2020-03-05 16:58:41 Manuscript Submission 2020-03-04 16:35:38 第二稿：疫情期间，补了实验 Stage Start Date Revision Received 2020-07-11 06:25:26 Waiting for Revision 2020-07-09 08:38:16 Decision Sent to Author 2020-07-09 08:38:16 Decision Pending 2020-06-29 08:28:42 Under Review 2020-06-25 09:38:03 Under Editorial Consideration 2020-06-23 10:09:56 Manuscript Submission 2020-04-09 14:44:05 第三稿：原则上已经接收，改了一下要求的格式 Stage Start Date Manuscript Ready for Publication 2020-07-16 10:45:24 Decision Sent to Author 2020-07-16 10:45:24 Decision Pending 2020-07-16 10:44:15 Under Review 2020-07-16 10:44:14 Under Editorial Consideration 2020-07-12 05:16:56 Manuscript Submission 2020-07-11 06:25:26 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5e55078563, createdName=Dr. X., createdTime=Fri Jul 17 16:20:42 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114057, encodeId=9208211405e1a, content=好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sat Feb 11 02:03:22 CST 2023, time=2023-02-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=804833, encodeId=4b7080483377, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Stage Start Date Decision Pending 2020-07-27 12:32:30 Under Review 2020-07-27 12:32:23 Under Editorial Consideration 2020-07-27 00:14:55 Initial QC 2020-07-23 09:04:59 Manuscript Submission 2020-07-18 06:59:50 这是我的文章状态，Dr.X你能给分析一下么？谢谢。我的Q是517861267, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:52:18 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108841, encodeId=a66721088411b, content=偏重的研究方向：癌症研究;肿瘤;EMT 经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b5b1736627, createdName=wawljwalj9232, createdTime=Wed Jan 04 22:25:42 CST 2023, time=2023-01-04, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=591364, encodeId=7ca3591364ca, content=二审两个小问题3天修回，pending decision到现在已经9天，CR最近这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2c732016445, createdName=lydia901717, createdTime=Thu May 21 09:18:00 CST 2020, time=2020-05-21, status=1, ipAttribution=)]

2020-07-28 silent111

审稿速度:1.0 | 投稿命中率:25.0
经验分享：Stage
Start Date
Decision Pending
2020-07-27 12:32:30
Under Review
2020-07-27 12:32:23
Under Editorial Consideration
2020-07-27 00:14:55
Initial QC
2020-07-23 09:04:59
Manuscript Submission
2020-07-18 06:59:50
这是我的文章状态，Dr.X你能给分析一下么？谢谢。我的Q是517861267

245 14

展开14条回复

[GetPortalCommentsPageByObjectIdResponse(id=2147876, encodeId=9bf2214e8765b, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：蛋白质翻译后修饰;肿瘤 经验分享：请问大家proof结束后多久能有排好版的文章上线啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:32:28 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2145679, encodeId=996121456e992, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投过三次，送外审会通知你。 第一次外审1个月，三个审稿人，意见都不乐观，被拒。改投oncogene，中。 第二次外审1个月，三个审稿意见，一个乐观，2个中性，大修后接受，从投稿到接受用了4个月。 第三次，合作文章，并列作者，秒拒。 编辑的态度不错，回复问题很及时。投稿系统bug非常多！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd8b8736567, createdName=ms4000000933785288, createdTime=Fri Jun 30 16:32:39 CST 2023, time=2023-06-30, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2109990, encodeId=f6a9210999082, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：比较难搞，第一稿 Stage Start Date Revision Received 2022-07-15 09:55:14 Waiting for Revision 2022-01-18 09:15:09 Decision Sent to Author 2022-01-18 09:15:09 Decision Pending 2022-01-18 07:43:20 Under Review 2021-12-15 16:40:12 Under Editorial Consideration 2021-12-15 10:25:39 Initial QC 2021-12-13 07:05:17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=482d4748397, createdName=hhhhhccc, createdTime=Thu Jan 12 20:15:37 CST 2023, time=2023-01-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2128280, encodeId=dbfb212828078, content=请问这个杂质接收以后需要提交原始数据吗？提交什么格式的原始数据呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5e1735331, createdName=爱的橙子蓝, createdTime=Tue Apr 25 18:42:56 CST 2023, time=2023-04-25, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=558040, encodeId=d91b55804092, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一稿，小修： Stage Start Date Waiting for Revision 2018-05-01 11:24:14 Decision Sent to Author 2018-05-01 11:24:14 Under Review 2018-04-30 17:54:03 Decision Pending 2018-04-30 17:53:41 Under Review 2018-04-02 16:34:31 Under Editorial Consideration 2018-04-02 15:53:37 Initial QC 2018-04-02 10:23:42 Manuscript Submission 2018-04-02 04:57:41 第二稿，格式修改： 编辑给重新写了摘要，改了标题。 Waiting for Revision 2018-06-08 13:31:15 Decision Sent to Author 2018-06-08 13:31:15 Under Review 2018-06-05 20:21:13 Decision Pending 2018-06-05 20:20:58 Under Review 2018-05-23 10:44:35 Under Editorial Consideration 2018-05-23 04:33:34 Manuscript Submission 2018-05-21 22:28:24 第三稿，接受： Stage Start Date Manuscript Ready for Publication 2018-06-15 11:20:47 Decision Sent to Author 2018-06-15 11:20:47 Under Review 2018-06-15 11:20:22 Decision Pending 2018-06-15 11:20:22 Under Review 2018-06-15 11:20:22 Under Editorial Consideration 2018-06-11 04:36:15 Manuscript Submission 2018-06-10 01:37:25 这个投稿系统附件图片不支持tiff，整到PDF里面分辨率又太低，来来回回跟编辑拉扯了好几次。感觉我们想法不重要，按他们说的来就好了。 希望后面的兄弟姐妹好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=743, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/04/5badf8a0248e81ed1f762a35444fa1de.jpg, createdBy=f1192053852, createdName=小小小蹄子, createdTime=Sat Jun 16 09:18:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803115, encodeId=5cd98031153d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：文章刚刚接收，贴个timeline，供大家参考： 第一稿 Stage Start Date Revision Received 2020-04-09 14:44:05 Waiting for Revision 2020-04-09 14:39:37 Decision Sent to Author 2020-04-09 14:39:37 Decision Pending 2020-04-06 17:45:32 Under Review 2020-03-07 11:36:22 Under Editorial Consideration 2020-03-06 13:06:37 Initial QC 2020-03-05 16:58:41 Manuscript Submission 2020-03-04 16:35:38 第二稿：疫情期间，补了实验 Stage Start Date Revision Received 2020-07-11 06:25:26 Waiting for Revision 2020-07-09 08:38:16 Decision Sent to Author 2020-07-09 08:38:16 Decision Pending 2020-06-29 08:28:42 Under Review 2020-06-25 09:38:03 Under Editorial Consideration 2020-06-23 10:09:56 Manuscript Submission 2020-04-09 14:44:05 第三稿：原则上已经接收，改了一下要求的格式 Stage Start Date Manuscript Ready for Publication 2020-07-16 10:45:24 Decision Sent to Author 2020-07-16 10:45:24 Decision Pending 2020-07-16 10:44:15 Under Review 2020-07-16 10:44:14 Under Editorial Consideration 2020-07-12 05:16:56 Manuscript Submission 2020-07-11 06:25:26 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5e55078563, createdName=Dr. X., createdTime=Fri Jul 17 16:20:42 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114057, encodeId=9208211405e1a, content=好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sat Feb 11 02:03:22 CST 2023, time=2023-02-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=804833, encodeId=4b7080483377, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Stage Start Date Decision Pending 2020-07-27 12:32:30 Under Review 2020-07-27 12:32:23 Under Editorial Consideration 2020-07-27 00:14:55 Initial QC 2020-07-23 09:04:59 Manuscript Submission 2020-07-18 06:59:50 这是我的文章状态，Dr.X你能给分析一下么？谢谢。我的Q是517861267, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:52:18 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108841, encodeId=a66721088411b, content=偏重的研究方向：癌症研究;肿瘤;EMT 经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b5b1736627, createdName=wawljwalj9232, createdTime=Wed Jan 04 22:25:42 CST 2023, time=2023-01-04, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=591364, encodeId=7ca3591364ca, content=二审两个小问题3天修回，pending decision到现在已经9天，CR最近这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2c732016445, createdName=lydia901717, createdTime=Thu May 21 09:18:00 CST 2020, time=2020-05-21, status=1, ipAttribution=)]

2023-01-04 wawljwalj9232 来自福建省

偏重的研究方向：癌症研究;肿瘤;EMT
经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊

99 0

[GetPortalCommentsPageByObjectIdResponse(id=2147876, encodeId=9bf2214e8765b, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：蛋白质翻译后修饰;肿瘤 经验分享：请问大家proof结束后多久能有排好版的文章上线啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e18315115, createdName=ms9000000602781212, createdTime=Thu Jul 13 17:32:28 CST 2023, time=2023-07-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2145679, encodeId=996121456e992, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投过三次，送外审会通知你。 第一次外审1个月，三个审稿人，意见都不乐观，被拒。改投oncogene，中。 第二次外审1个月，三个审稿意见，一个乐观，2个中性，大修后接受，从投稿到接受用了4个月。 第三次，合作文章，并列作者，秒拒。 编辑的态度不错，回复问题很及时。投稿系统bug非常多！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd8b8736567, createdName=ms4000000933785288, createdTime=Fri Jun 30 16:32:39 CST 2023, time=2023-06-30, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2109990, encodeId=f6a9210999082, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤研究 经验分享：比较难搞，第一稿 Stage Start Date Revision Received 2022-07-15 09:55:14 Waiting for Revision 2022-01-18 09:15:09 Decision Sent to Author 2022-01-18 09:15:09 Decision Pending 2022-01-18 07:43:20 Under Review 2021-12-15 16:40:12 Under Editorial Consideration 2021-12-15 10:25:39 Initial QC 2021-12-13 07:05:17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=482d4748397, createdName=hhhhhccc, createdTime=Thu Jan 12 20:15:37 CST 2023, time=2023-01-12, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2128280, encodeId=dbfb212828078, content=请问这个杂质接收以后需要提交原始数据吗？提交什么格式的原始数据呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7d5e1735331, createdName=爱的橙子蓝, createdTime=Tue Apr 25 18:42:56 CST 2023, time=2023-04-25, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=558040, encodeId=d91b55804092, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：第一稿，小修： Stage Start Date Waiting for Revision 2018-05-01 11:24:14 Decision Sent to Author 2018-05-01 11:24:14 Under Review 2018-04-30 17:54:03 Decision Pending 2018-04-30 17:53:41 Under Review 2018-04-02 16:34:31 Under Editorial Consideration 2018-04-02 15:53:37 Initial QC 2018-04-02 10:23:42 Manuscript Submission 2018-04-02 04:57:41 第二稿，格式修改： 编辑给重新写了摘要，改了标题。 Waiting for Revision 2018-06-08 13:31:15 Decision Sent to Author 2018-06-08 13:31:15 Under Review 2018-06-05 20:21:13 Decision Pending 2018-06-05 20:20:58 Under Review 2018-05-23 10:44:35 Under Editorial Consideration 2018-05-23 04:33:34 Manuscript Submission 2018-05-21 22:28:24 第三稿，接受： Stage Start Date Manuscript Ready for Publication 2018-06-15 11:20:47 Decision Sent to Author 2018-06-15 11:20:47 Under Review 2018-06-15 11:20:22 Decision Pending 2018-06-15 11:20:22 Under Review 2018-06-15 11:20:22 Under Editorial Consideration 2018-06-11 04:36:15 Manuscript Submission 2018-06-10 01:37:25 这个投稿系统附件图片不支持tiff，整到PDF里面分辨率又太低，来来回回跟编辑拉扯了好几次。感觉我们想法不重要，按他们说的来就好了。 希望后面的兄弟姐妹好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=743, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/04/5badf8a0248e81ed1f762a35444fa1de.jpg, createdBy=f1192053852, createdName=小小小蹄子, createdTime=Sat Jun 16 09:18:00 CST 2018, time=2018-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803115, encodeId=5cd98031153d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：文章刚刚接收，贴个timeline，供大家参考： 第一稿 Stage Start Date Revision Received 2020-04-09 14:44:05 Waiting for Revision 2020-04-09 14:39:37 Decision Sent to Author 2020-04-09 14:39:37 Decision Pending 2020-04-06 17:45:32 Under Review 2020-03-07 11:36:22 Under Editorial Consideration 2020-03-06 13:06:37 Initial QC 2020-03-05 16:58:41 Manuscript Submission 2020-03-04 16:35:38 第二稿：疫情期间，补了实验 Stage Start Date Revision Received 2020-07-11 06:25:26 Waiting for Revision 2020-07-09 08:38:16 Decision Sent to Author 2020-07-09 08:38:16 Decision Pending 2020-06-29 08:28:42 Under Review 2020-06-25 09:38:03 Under Editorial Consideration 2020-06-23 10:09:56 Manuscript Submission 2020-04-09 14:44:05 第三稿：原则上已经接收，改了一下要求的格式 Stage Start Date Manuscript Ready for Publication 2020-07-16 10:45:24 Decision Sent to Author 2020-07-16 10:45:24 Decision Pending 2020-07-16 10:44:15 Under Review 2020-07-16 10:44:14 Under Editorial Consideration 2020-07-12 05:16:56 Manuscript Submission 2020-07-11 06:25:26 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5e55078563, createdName=Dr. X., createdTime=Fri Jul 17 16:20:42 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114057, encodeId=9208211405e1a, content=好久没看CR, 这些年新崛起的cancer期刊越来越多，很多老牌杂志挺不容易,一年不如一年，不如早日放下身段, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Sat Feb 11 02:03:22 CST 2023, time=2023-02-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=804833, encodeId=4b7080483377, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：Stage Start Date Decision Pending 2020-07-27 12:32:30 Under Review 2020-07-27 12:32:23 Under Editorial Consideration 2020-07-27 00:14:55 Initial QC 2020-07-23 09:04:59 Manuscript Submission 2020-07-18 06:59:50 这是我的文章状态，Dr.X你能给分析一下么？谢谢。我的Q是517861267, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=245, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:52:18 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108841, encodeId=a66721088411b, content=偏重的研究方向：癌症研究;肿瘤;EMT 经验分享：难发不代表质量高，这几年cr的质量，尤其是国外的作者发的，也不咋地。吃老本的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b5b1736627, createdName=wawljwalj9232, createdTime=Wed Jan 04 22:25:42 CST 2023, time=2023-01-04, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=591364, encodeId=7ca3591364ca, content=二审两个小问题3天修回，pending decision到现在已经9天，CR最近这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2c732016445, createdName=lydia901717, createdTime=Thu May 21 09:18:00 CST 2020, time=2020-05-21, status=1, ipAttribution=)]

2020-05-21 lydia901717

二审两个小问题3天修回，pending decision到现在已经9天，CR最近这么慢？

194 5

展开5条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务